Irbesartan prevents sodium channel remodeling in a canine model of atrial fibrillation

Effect of irbesartan on development of atrial fibrosis and atrial fibrillation in a canine atrial tachycardia model with left ventricular dysfunction, association with p53

(2016) Naoya Kataoka et al.   HEART AND VESSELS

Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation

(2016) Yu-Cheng Hsieh et al.   MEDICINE

Angiotensin-(1-7) Prevent Atrial Tachycardia Induced Sodium Channel Remodeling

(2014) XUEWEN WANG et al.   PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY

Irbesartan-mediated AT1 receptor blockade attenuates hyposmotic-induced enhancement of IKs current and prevents shortening of action potential duration in atrial myocytes

(2013) Jie Wu et al.   JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action

(2012) Hyoung Kyu Kim et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY

Angiotensin-(1–7) prevents atrial fibrosis and atrial fibrillation in long-term atrial tachycardia dogs

(2010) Enzhao Liu et al.   REGULATORY PEPTIDES

Inhibitory effects of tetrandrine on the Na+ channel of human atrial fibrillation myocardium

(2009) Li Chen et al.   ACTA PHARMACOLOGICA SINICA

Enalapril, irbesartan, and angiotensin-(1–7) prevent atrial tachycardia-induced ionic remodeling

(2009) Enzhao Liu et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

NF-κB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II

(2007) Lijuan L. Shang et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY